Sustainable Development Goal 3

LONGi and Power Solution jointly launch SDG Project "Light Up Africa" at World Economic Forum 2024 in Davos

Retrieved on: 
Thursday, January 18, 2024
Well, Sustainable Development Goal 6, SDG, Congress Center, World Economic Forum, Social, Partnership, Electricity, Gender equality, WEF, Sanitation, LONGi, SDG7, Quality of life, BOP, Sustainable Development Goals, LONGi Green Energy Technology, Social entrepreneurship, United Nations, GLN, Sustainable Development Goal 3, Poverty, Education, Sustainable Development Goal 4, Cell, Renewable energy

Li Xia received the 2024 Schwab Foundation Social Innovation Awards--Social Entrepreneurs in Davos. Li Xia was the only recipient from China this year and is the first Chinese woman to be honored for this award.

Key Points: 
  • DAVOS, Switzerland, Jan. 18, 2024 /PRNewswire/ -- The World Economic Forum Annual Meeting 2024 officially kicked off in Davos, Switzerland, with the theme "Rebuilding Trust".
  • Dennis She, Vice President of LONGi held a talk with Li Xia, Chief Executive Officer of Shenzhen Power Solution at the World Economic Forum Congress Center.
  • They both shared the best practices of affordable solar power solutions for poverty alleviation, especially for the population at the bottom of the economic pyramid.
  • The World Economic Forum recognized LONGi for the innovative adaptation of intelligent technologies to promote intelligent solar products manufacturing.

LONGi and Power Solution jointly launch SDG Project "Light Up Africa" at World Economic Forum 2024 in Davos

Retrieved on: 
Thursday, January 18, 2024
Well, Sustainable Development Goal 6, SDG, Congress Center, World Economic Forum, Social, Multimedia, Partnership, Electricity, Gender equality, WEF, Sanitation, LONGi, SDG7, Quality of life, BOP, Sustainable Development Goals, LONGi Green Energy Technology, Social entrepreneurship, United Nations, GLN, Sustainable Development Goal 3, Poverty, Education, Sustainable Development Goal 4, Cell, Renewable energy

Li Xia received the 2024 Schwab Foundation Social Innovation Awards--Social Entrepreneurs in Davos. Li Xia was the only recipient from China this year and is the first Chinese woman to be honored for this award.

Key Points: 
  • DAVOS, Switzerland, Jan. 17, 2024 /PRNewswire/ -- The World Economic Forum Annual Meeting 2024 officially kicked off in Davos, Switzerland, with the theme "Rebuilding Trust".
  • Dennis She, Vice President of LONGi held a talk with Li Xia, Chief Executive Officer of Shenzhen Power Solution at the World Economic Forum Congress Center.
  • "Joining hands with LONGi will allow Power Solution offer more innovative solutions in the future for African countries", added Li Xia.
  • The World Economic Forum recognized LONGi for the innovative adaptation of intelligent technologies to promote intelligent solar products manufacturing.

Global HIV Treatment Market Analysis Report 2023: A $25+ Billion Market by 2030 - Focus on Combination Therapies Gaining Momentum - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 29, 2023
AIDS, Pharmaceutical, Health, Hetero Drugs, Telehealth, Gilead Sciences, Drug development, EU, The, Prevalence, HIV, Islatravir, Sun Pharma, MPP, Public, Sustainable Development Goal 3, COVID-19, Collaboration, Health equity, Quality of life, Hope, ART, Research, ViiV Healthcare, Cipla, Medicines Patent Pool, Drug resistance, Non-governmental organization, Patient, Risk, Mylan, Hook effect, Aurobindo Pharma, Sustainable Development Goals, Artificial intelligence, Growth, Merck, FDA, UNAIDS, Pharmaceutical industry, Vaccine, Medical device, Bictegravir/emtricitabine/tenofovir alafenamide, Tenofovir alafenamide, Capsid, Dolutegravir/lamivudine, Lenacapavir, Dolutegravir/rilpivirine, Generic

The "Global HIV Treatment Market: Analysis By Product, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global HIV Treatment Market: Analysis By Product, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global HIV treatment market in 2022 stood at US$22.38 billion, and is likely to reach US$25.49 billion by 2030.
  • The global HIV treatment market is projected to grow at a CAGR of 1.42% during the forecast period of 2023-2030.
  • These ongoing efforts are instrumental in shaping the future of the global HIV treatment market.

After a decades-long fight against malaria, Belize is certified malaria-free by the World Health Organization

Retrieved on: 
Wednesday, June 21, 2023
Our Lady, Queen of the Americas (Washington, D.C.), Volunteering, Sustainable Development Goal 3, Tuberculosis, Inter-American Development Bank, Community, The Global Fund to Fight AIDS, Tuberculosis and Malaria, PAHO, United Nations Foundation, Pan American Health Organization, Bill & Melinda Gates Foundation, Movement, Government, International development, Death, UN, Sustainable Development Goals, Bill, Diagnosis, Pregnancy, WHO, Health, World Health Organization, Disease, Vaccine, Malaria, United

WASHINGTON, June 21, 2023 /PRNewswire-PRWeb/ -- The World Health Organization (WHO) has certified Belize for achieving malaria elimination, a significant milestone more than 70 years in the making. Belize becomes the second Central American country, after El Salvador, and 42nd country (plus one territory) worldwide to receive malaria-free certification.

Key Points: 
  • Belize becomes the second Central American country, after El Salvador, and 42nd country (plus one territory) worldwide to receive malaria-free certification.
  • "Belize is the latest success story in the decades-long global fight to end malaria," said United Nations Foundation President and CEO Elizabeth Cousens.
  • "This milestone is a testament to the power of sustained government commitment and strategic partnerships across borders, sectors, and communities.
  • The Pan American Health Organization (PAHO), a longtime technical partner, has helped the Belize government build its capacity for prompt malaria diagnosis, treatment, and surveillance.

ViiV Healthcare and the Medicines Patent Pool Sign New Voluntary Licensing Agreement to Expand Access to Innovative Long-Acting HIV Prevention Medicine

Retrieved on: 
Thursday, July 28, 2022
Biotechnology, Infectious Diseases, AIDS, Health, Pharmaceutical, Infection, HIV-positive people, Diagnosis, Sale, Acquisition, Rash, LA, Sustainable Development Goals, Fever, Food, Use, ViiV Healthcare, Woman, CEO, HIV-1, STI, Medicines Patent Pool, Partnership, Fatigue, Risk, Shionogi, Partner (business rank), MPP, US, Myalgia, Pre-exposure prophylaxis, US FDA, News, Pfizer, GSK, US Foods, FDA, Adolescence, Sustainable Development Goal 3, Central Public Security Comprehensive Management Commission, Subtypes of HIV, HIV, Unitaid, Fortis Healthcare, Non-governmental organization, Condom, Medicine, Pharmaceutical industry, Birth control, Vaccine

Access to an effective long-acting HIV prevention option could significantly contribute towards the goal of ending the epidemic.

Key Points: 
  • Access to an effective long-acting HIV prevention option could significantly contribute towards the goal of ending the epidemic.
  • In particular, voluntary licensing has enabled access to generic products containing another of ViiV Healthcares innovative medicines, dolutegravir, for at least 20 million people living with HIV in low- and middle-income countries, as of December 20214.
  • Deborah Waterhouse, CEO at ViiV Healthcare said, Todays announcement represents a potentially game-changing moment in HIV prevention.
  • Charles Gore, MPP Executive Director said, We are delighted to sign this voluntary licence with ViiV for cabotegravir LA for PrEP.

Autoliv launches multi-year commitment to support the UN Road Safety Fund

Retrieved on: 
Tuesday, April 12, 2022
SSE, Autoliv, Sustainable Development Goals, NEW, Private sector, Death, NYSE, Health, CEO, SDG, Thought, Injury, Safety, Knowledge, Sustainable Development Goal 3, Lists of countries and territories, Crash, The Second Decade (1993–2003), Awareness, Road, Transport

Road traffic crashes claim 1.35 million lives every year and are the leading cause of death among children and young adults.

Key Points: 
  • Road traffic crashes claim 1.35 million lives every year and are the leading cause of death among children and young adults.
  • Autoliv's support of UNRSF is an important step to further democratize road safety and increase awareness and availability of life-saving products where it is most needed.
  • "As a member of the multi-stakeholder UNRSF Platforms of Engagement , Autoliv directly supports UNRSF thinking on high-impact road safety projects.
  • Autoliv's commitment to support the UNRSF will directly result in road safety interventions in low- and middle-income countries ranging from better vehicle standards and road infrastructure design to effective systems to improve road user behavior and emergency post-crash response.

Autoliv launches multi-year commitment to support the UN Road Safety Fund

Retrieved on: 
Tuesday, April 12, 2022
SSE, Autoliv, Sustainable Development Goals, NEW, Private sector, Death, NYSE, Health, CEO, SDG, Thought, Injury, Safety, Knowledge, Sustainable Development Goal 3, Lists of countries and territories, Crash, The Second Decade (1993–2003), Awareness, Road, Transport

Road traffic crashes claim 1.35 million lives every year and are the leading cause of death among children and young adults.

Key Points: 
  • Road traffic crashes claim 1.35 million lives every year and are the leading cause of death among children and young adults.
  • Autoliv's support of UNRSF is an important step to further democratize road safety and increase awareness and availability of life-saving products where it is most needed.
  • "As a member of the multi-stakeholder UNRSF Platforms of Engagement , Autoliv directly supports UNRSF thinking on high-impact road safety projects.
  • Autoliv's commitment to support the UNRSF will directly result in road safety interventions in low- and middle-income countries ranging from better vehicle standards and road infrastructure design to effective systems to improve road user behavior and emergency post-crash response.

The CREB-binding protein (CBP)/beta-catenin inhibitor E7386, co-created by Eisai and PRISM BioLab, achieved the clinical POC (Proof of Concept)

Retrieved on: 
Monday, November 1, 2021
Dai, Fibrosis, CREB-binding protein, Neurology, Sustainable Development Goal 3, Cancer, Research, Organogenesis, Cell proliferation, RAS, MYC, Atomic mass, Merck, PRISM, Sustainable Development Goals, CBP, Patient, Drug discovery, Achievement, Oncology, Differentiable function, POC, Hepatocellular carcinoma, APC, Merck & Co., Wnt signaling pathway, Senior, Gastrulation, CEO, Biomarker, Mammal, Drosophila, Morphogenesis, Adenomatous polyposis coli, Pembrolizumab, PCP, Gene expression, Pharmaceutical industry

The E7386 targets, beta-catenin, is considered to be one of the undruggable targets that are particularly difficult to develop into drug discovery.

Key Points: 
  • The E7386 targets, beta-catenin, is considered to be one of the undruggable targets that are particularly difficult to develop into drug discovery.
  • E7386 is a CBP / beta-catenin inhibitor that inhibits CBP and beta-catenin protein-protein interactions and regulates the Wnt signal-dependent gene expression.
  • (1)
    Based on the POC achievement, Eisai has initiated a phase Ib/II clinical trial (Study 201) of E7386 in combination with anti-PD-1 therapy pembrolizumab for solid tumors in Japan.
  • E7386 is a CBP / beta-catenin inhibitor that inhibits protein-protein interactions between the transcription coactivator CBP and beta-catenin, and regulates the Wnt signaling-dependent gene expression.

Fujitsu and University of Tokyo Hospital Embark on Joint Research into AI to Aid the Fight Against Heart Disease

Retrieved on: 
Monday, October 11, 2021
Patient, Hospital, AI, ICT, Electrocardiography, United Nations, Department, Data analysis, First Nations in Ontario, Arrhythmia, Heart, US, Goal, Vital statistics, Diagnosis, Degenerative disease, Ministry of Health (Saudi Arabia), Research, TDA, Trust, University, Cardiovascular disease, Movement, Heart sounds, Sustainable Development Goals, Death, Echocardiography, Fujitsu, Healthy Living, Solution, Disease, Muscle tissue, Ministry, Technology, Sustainable Development Goal 3, Medical device, Medical imaging

Since December 2019, Fujitsu has been making progress with research and development of proprietary AI technology(2) in collaboration with the University of Tokyo Hospital.

Key Points: 
  • Since December 2019, Fujitsu has been making progress with research and development of proprietary AI technology(2) in collaboration with the University of Tokyo Hospital.
  • The AI will be used in clinical field research to estimate the presence or absence of abnormal heart movements based on the data of patients undergoing electrocardiographic procedures at the University of Tokyo Hospital.
  • Based on the electrocardiogram data of patients examined at the University of Tokyo Hospital, Fujitsu and the University of Tokyo Hospital will verify the effectiveness of detection of abnormal heart movement by AI.
  • Through its joint research with the University of Tokyo Hospital, Fujitsu will continue to actively promote research and development of AI to detect various heart diseases.